Elranatamab Biosimilar – Anti-TNFRSF17;CD3E mAb – Research Grade

Description of Elranatamab Biosimilar - Anti-TNFRSF17;CD3E mAb - Research Grade

Introduction

Elranatamab Biosimilar is a monoclonal antibody (mAb) that targets two important proteins, TNFRSF17 and CD3E. This unique combination makes it a promising therapeutic option for a variety of diseases. In this article, we will explore the structure, activity, and potential applications of Elranatamab Biosimilar as a research-grade antibody.

Structure of Elranatamab Biosimilar

Elranatamab Biosimilar is a recombinant, humanized IgG1 kappa monoclonal antibody. It is composed of two identical heavy chains and two identical light chains, each containing variable and constant regions. The variable region of the antibody is responsible for binding to its target proteins, TNFRSF17 and CD3E. The constant region, on the other hand, determines the antibody’s effector functions, such as complement activation and antibody-dependent cellular cytotoxicity (ADCC).

Activity of Elranatamab Biosimilar

Elranatamab Biosimilar is a bispecific antibody, meaning it can bind to two different targets simultaneously. Its unique structure allows it to bind to both TNFRSF17 and CD3E with high affinity and specificity. TNFRSF17, also known as B-cell maturation antigen (BCMA), is a cell surface receptor that is highly expressed on the surface of multiple myeloma cells. By binding to TNFRSF17, Elranatamab Biosimilar can block its signaling pathway, leading to the inhibition of tumor growth and survival. CD3E, on the other hand, is a component of the T-cell receptor complex. By binding to CD3E, Elranatamab Biosimilar can activate T-cells and induce their cytotoxic activity against cancer cells.

Potential Applications of Elranatamab Biosimilar

Elranatamab Biosimilar has shown promising results in pre-clinical studies as a potential therapeutic option for multiple myeloma and other B-cell malignancies. In a phase 1 clinical trial, it demonstrated a favorable safety profile and significant anti-tumor activity in patients with relapsed or refractory multiple myeloma. Its bispecific nature makes it a potential candidate for combination therapy with other anti- cancer drugs. Additionally, Elranatamab Biosimilar has also shown potential in the treatment of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. By targeting TNFRSF17, it can modulate the immune response and reduce inflammation.

Conclusion

In conclusion, Elranatamab Biosimilar is a promising research-grade antibody that targets two important proteins, TNFRSF17 and CD3E. Its unique bispecific structure allows it to bind to both targets simultaneously, making it a potential therapeutic option for a variety of diseases, including multiple myeloma and autoimmune disorders. Further clinical trials are needed to fully explore the potential of this antibody and its combination with other therapies. With its high specificity and favorable safety profile, Elranatamab Biosimilar holds great promise in the field of antibody-based therapeutics.